Analystreport

Xenon Pharmaceuticals Inc (NASDAQ: XENE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. They now have a $14.00 price target on the stock.

Xenon Pharmaceuticals Inc. - Common Shares  (XENE) 
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.xenon-pharma.com